The European Medicines Agency (EMA), the EU's drug regulator, is expected to decide in early October on the possible use of a booster dose of the Pfizer (NYSE:PFE)/BioNTech (Nasdaq:BNTX) COVID-19 vaccine, Reuters news agency reported on Thursday, citing a source with direct knowledge of the matter.
According to the source, this will be the EMA's first decision on COVID-19 vaccine boosters.
The regulator said on 6 September that it had begun its evaluation of data submitted by Pfizer and BioNTech for a booster dose to be given six months after the second dose in people 16 years of age and older.
Oncopeptides plans EMA filing to broaden Pepaxti indication
GSK partners with SBP Group to accelerate China launch of bepirovirsen
Harbour BioMed's HBM7004 receives US FDA IND clearance for Phase I trial
Mabwell's clinical trial application for 9MW5211 cleared by US FDA
Innovent's IBI363 receives third Chinese regulatory BTD for MSS/pMMR CRC
European Commission approves Bristol Myers Squibb's Sotyktu for psoriatic arthritis
Rznomics receives FDA RMAT designation for HCC candidate RZ‑001
BioArctic and Eisai report FDA extension of Leqembi Iqlik review
Mezzion reveals pre-IND FDA feedback on udenafil development in ADPKD